Anticoagulation management in mechanical circulatory support

Journal of Thoracic Disease

Volumn 7, Issue 12, 2015, Pages 2129-2138

  Adatya, Sirtaz ^a   Bennett, Mosi K ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Acquired von Willebrand syndrome; Anti factor Xa (anti FXa); Anticoagulation; Continuous flow left ventricular assist device (CFLVAD); Device thrombosis; Mean arterial pressure; Mechanical circulatory support

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANEMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; DABIGATRAN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN;

ANEMIA; ANGIOGENESIS; ANTICOAGULANT THERAPY; ASSISTED CIRCULATION; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL (TOPIC); CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICE; HEART FAILURE; HEART TRANSPLANTATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; MEDICAL DEVICE COMPLICATION; PARTIAL THROMBOPLASTIN TIME; PATIENT SAFETY; PLASMAPHERESIS; PULSE PRESSURE; REVIEW; RISK FACTOR; THROMBOSIS; TURBULENT FLOW; VENTRICULAR ASSIST DEVICE; VENTRICULAR ASSIST DEVICE THROMBOSIS; VON WILLEBRAND DISEASE;

EID: 84954159758     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2015.10.65     Document Type: Review

References (49)

1. Starling RC, Moazami N, Silvestry SC, et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med 2014;370:33-40.
2. Kirklin JK, Naftel DC, Kormos RL, et al. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. J Heart Lung Transplant 2014;33:12-22.
3. Najjar SS, Slaughter MS, Pagani FD, et al. An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial. J Heart Lung Transplant 2014;33:23-34.
4. Pagani FD, Milano CA, Tatooles AJ, et al. HeartWare HVAD for the Treatment of Patients With Advanced Heart Failure Ineligible for Cardiac Transplantation: Results of the ENDURANCE Destination Therapy Trial. ISHLT 35th Annual Meeting. Nice, France, 2015.
5. Food and Drug Administration. Serious Adverse Events with Implantable Left Ventricular Assist Devices (LVADs): FDA Safety Communication. Available online: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm457327.htm
6. Görlinger K, Bergmann L, Dirkmann D. Coagulation management in patients undergoing mechanical circulatory support. Best Pract Res Clin Anaesthesiol 2012;26:179-98.
7. Eckman PM, John R. Bleeding and thrombosis in patients with continuous-flow ventricular assist devices. Circulation 2012;125:3038-47.
8. Klovaite J, Gustafsson F, Mortensen SA, et al. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol 2009;53:2162-7.
9. Uriel N, Pak SW, Jorde UP, et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol 2010;56:1207-13.
10. Heyde EC. Gastrointestinal bleeding in aortic stenosis. N Engl J Med 1958;259:196.
11. Warkentin TE, Moore JC, Morgan DG. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand's disease the link? Lancet 1992;340:35-7.
12. Vincentelli A, Susen S, Le Tourneau T, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003;349:343-9.
13. Crow S, Chen D, Milano C, et al. Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. Ann Thorac Surg 2010;90:1263-9; discussion 1269.
14. Crow S, John R, Boyle A, et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg 2009;137:208-15.
15. Meyer AL, Malehsa D, Budde U, et al. Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device. JACC Heart Fail 2014;2:141-5.
16. Moake JL, Turner NA, Stathopoulos NA, et al. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986;78:1456-61.
17. Geisen U, Heilmann C, Beyersdorf F, et al. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. Eur J Cardiothorac Surg 2008;33:679-84.
18. Bartoli CR, Restle DJ, Zhang DM, et al. Pathologic von Willebrand factor degradation with a left ventricular assist device occurs via two distinct mechanisms: mechanical demolition and enzymatic cleavage. J Thorac Cardiovasc Surg 2015;149:281-9.
19. Cappell MS, Lebwohl O. Cessation of recurrent bleeding from gastrointestinal angiodysplasias after aortic valve replacement. Ann Intern Med 1986;105:54-7.
20. Letsou GV, Shah N, Gregoric ID, et al. Gastrointestinal bleeding from arteriovenous malformations in patients supported by the Jarvik 2000 axial-flow left ventricular assist device. J Heart Lung Transplant 2005;24:105-9.
21. Slaughter MS. Hematologic effects of continuous flow left ventricular assist devices. J Cardiovasc Transl Res 2010;3:618-24.
22. Wever-Pinzon O, Selzman CH, Drakos SG, et al. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail 2013;6:517-26.
23. Zhang DM, Kang J, Restle DJ, et al. LVAD-Associated von Willebrand Factor Degradation Alters Angiogenesis: A Mechanistic Link Between LVAD Support, Gastrointestinal Angiodysplasia, and Bleeding? The Journal of Heart and Lung Transplantation 2015;34:S13.
24. Mehra MR, Stewart GC, Uber PA. The vexing problem of thrombosis in long-term mechanical circulatory support. J Heart Lung Transplant 2014;33:1-11.
25. Boyle AJ, Jorde UP, Sun B, et al. Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients. J Am Coll Cardiol 2014;63:880-8.
26. Goldstein DJ, John R, Salerno C, et al. Algorithm for the diagnosis and management of suspected pump thrombus. J Heart Lung Transplant 2013;32:667-70.
27. Ballew CC, Benton EM, Groves DS, et al. Comparing Survival of HMII Patients with Elevated LDH: Implications for Medical and Surgical Management. The Journal of Heart and Lung Transplantation 2013;32:S38.
28. Koene RJ, Win S, Naksuk N, et al. HAS-BLED and CHA2DS2-VASc scores as predictors of bleeding and thrombotic risk after continuous-flow ventricular assist device implantation. J Card Fail 2014;20:800-7.
29. Blitz A. Pump thrombosis-A riddle wrapped in a mystery inside an enigma. Ann Cardiothorac Surg 2014;3:450-71.
30. Katz JN, Adamson RM, John R, et al. Safety of reduced anti-thrombotic strategies in HeartMate II patients: A one-year analysis of the US-TRACE Study. J Heart Lung Transplant 2015;34:1542-8.
31. Adatya S, Uriel N, Yarmohammadi H, et al. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support. JACC Heart Fail 2015;3:314-22.
32. Adatya S, John R, Eckman PM. Treatment of hemolysis with intravenous unfractionated heparin using an antifactor Xa-based monitoring protocol. J Thorac Cardiovasc Surg 2015;149:1465-6.
33. Sandner SE, Riebandt J, Haberl T, et al. Low-molecularweight heparin for anti-coagulation after left ventricular assist device implantation. J Heart Lung Transplant 2014;33:88-93.
34. Feldman D, Pamboukian SV, Teuteberg JJ, et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant 2013;32:157-87.
35. Blais DM, Sun B, Vesco P, et al. Profound thrombocytopenia with glycoprotein IIb/IIIa inhibitors plus heparin for pump thrombus. J Heart Lung Transplant 2008;27:1361-2.
36. Al-Quthami AH, Jumean M, Kociol R, et al. Eptifibatide for the treatment of HeartMate II left ventricular assist device thrombosis. Circ Heart Fail 2012;5:e68-70.
37. Tellor BR, Smith JR, Prasad SM, et al. The use of eptifibatide for suspected pump thrombus or thrombosis in patients with left ventricular assist devices. J Heart Lung Transplant 2014;33:94-101.
38. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-29.
39. Badiye A, Hernandez GA, Chaparro S. Argatroban as novel therapy for suspected thrombosis in patients with continuous-flow left ventricle assist device and hemolysis. ASAIO J 2014;60:361-5.
40. Schlendorf K, Patel CB, Gehrig T, et al. Thrombolytic therapy for thrombosis of continuous flow ventricular assist devices. J Card Fail 2014;20:91-7.
41. Prasad SM, Robertson JO, Itoh A, et al. Histologic analysis of clots in explanted axial continuous-flow left ventricular assist devices. J Heart Lung Transplant 2015;34:616-8.
42. Nassif ME, Patel JS, Shuster JE, et al. Clinical outcomes with use of erythropoiesis stimulating agents in patients with the HeartMate II left ventricular assist device. JACC Heart Fail 2015;3:146-53.
43. Vrtovec B, Radovancevic R, Delgado RM, et al. Significance of anaemia in patients with advanced heart failure receiving long-term mechanical circulatory support. Eur J Heart Fail 2009;11:1000-4.
44. Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:340S-380S.
45. Zucker MJ, Sabnani I, Baran DA, et al. Cardiac transplantation and/or mechanical circulatory support device placement using heparin anti-coagulation in the presence of acute heparin-induced thrombocytopenia. J Heart Lung Transplant 2010;29:53-60.
46. Pötzsch B, Klövekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 2000;343:515.
47. Koster A, Loebe M, Mertzlufft F, et al. Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GP IIb/IIIa inhibitor tirofiban as anticoagulant. Ann Thorac Surg 2000;70:2160-1.
48. Dyke CM, Smedira NG, Koster A, et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 2006;131:533-9.
49. Welsby IJ, Um J, Milano CA, et al. Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg 2010;110:30-5.